880769-28-8 Usage
Description
2-[2-[(3S)-3-[3-[(1E)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-chloropropyl]phenyl]-2-propanol is a complex organic compound with a unique molecular structure. It is characterized by its chiral centers, double bond, and various functional groups, which contribute to its specific properties and potential applications.
Uses
Used in Pharmaceutical Industry:
2-[2-[(3S)-3-[3-[(1E)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-chloropropyl]phenyl]-2-propanol is used as an intermediate in the synthesis of Montelukast (M568000), a leukotriene antagonist. Montelukast is a medication used to prevent and treat asthma, allergic rhinitis, and other respiratory conditions by blocking the action of leukotrienes, which are inflammatory mediators.
Used in Research and Development:
Due to its unique structure and properties, 2-[2-[(3S)-3-[3-[(1E)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-chloropropyl]phenyl]-2-propanol may also be utilized in research and development for the discovery of new pharmaceutical compounds, drug delivery systems, or as a building block for the synthesis of other complex organic molecules. Its potential applications in various fields can be further explored through scientific studies and innovative approaches.
Check Digit Verification of cas no
The CAS Registry Mumber 880769-28-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,0,7,6 and 9 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 880769-28:
(8*8)+(7*8)+(6*0)+(5*7)+(4*6)+(3*9)+(2*2)+(1*8)=218
218 % 10 = 8
So 880769-28-8 is a valid CAS Registry Number.
880769-28-8Relevant articles and documents
PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS
-
Page/Page column 10, (2011/04/14)
-
A PROCESS FOR THE PREPARATION OF MONTELUKAST
-
Page/Page column 17-18, (2010/11/25)
The present invention relates to a process for the preparation of Montelukast or a salt thereof comprises, i) condensing Methyl -2-[3-[3-(2-(7 - chloroquinolin -2-yl) ethenyl] phenyl] -3 -chloro propyljbenzoate obtained above with l-(mercaptomethyl) cyclopropane acetic acid in presence of alkali carbonates such as Cesium Carbonate, followed by salification with organic amine ii) neutralizing the organic amine salt as obtained above with organic/inorganic acid followed by reaction with methylmagnesium chloride in the presence of Cerium Chloride followed by treatment with organic base yields montelukast amine salt iii) converting the montelukast amine salt to Montelukast Free acid iv) saltification of Montelukast free acid with Sodium hydroxide affords Montelukast Sodium.
